Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.

ABSTRACT:

Background

Human leukocyte antigen class 1 (HLA-1)-dependent immune activity is linked to autoimmune diseases. HLA-1-dependent CD8⁺ T cells are required for immune checkpoint blockade antitumor activity. It is unknown if HLA-1 genotype is predictive of toxicity to immune checkpoint blockade.

Methods

Patients with advanced solid tumors stratified into 5 cohorts received single agent pembrolizumab (anti-programmed cell death-1) 200 mg intravenously every 3 weeks in an investigator-initiated phase II trial (Investigator-Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation study, NCT02644369). Germline whole-exome sequencing of peripheral blood mononuclear cells was performed using the Illumina HiSeq2500 platform. HLA-1 haplotypes were predicted

SUBMITTER: Iafolla MAJ 

PROVIDER: S-EPMC7853183 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature